Table 1

Patient characteristics

Boys, number (%)144 (69.9%)
Age, mean (SD)10.4 years (3.7)
BMI, mean (SD)17.2 (3.1)
Asthma maintenance therapy, n (%)195 (94.7)
 ICS ≤250 μg/day*143 (73.3%)
 ICS 251–500 μg/day44 (22.5%)
 ICS >500 μg/day1 (<1%)
 Combination therapy (ICS+LABA)51 (26.1%)
Allergic rhinitis therapy, n (%)105 (51%)
 Nasal corticosteroids43 (40.9%)
 Oral antihistamines19 (18.1%)
 Montelukast4 (3.8%)
 Combination31 (29.5%)
FVC, mean (SD)101.3% pred (12.0)
FEV1, mean (SD)100.3% pred (14.7)
FeNO, median (IQR)12.5 ppb (0–24)
IgE, median (IQR)247 kU/litre (55–702)
  • * Daily dose of fluticasone (or equivalent).

  • BMI, body mass index (body weight (in kg) divided by height (in cm) squared); ICS, inhaled corticosteroids; LABA, long-acting β agonist; FeNO, fraction of nitric oxide in exhaled air; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; pred, predicted.